title: [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
abstract: The frequency of venous and arterial thromboses and plasminogen level were investigated in 78 patients with antiphospholipid syndrome (APS), 35 of whom with systemic lupus erythematosus (SLE+APS) and 43 - with primary APS (PAPS). The levels and genotype of plasminogen activator inhibitor type 1 (PAI-1) were determined in 45 patients with APS, of whom 21 patients with SLE + APS and 24 patients with PAPS. A control group included 10 healthy individuals without autoimmune disease signs and thromboses on period of investigation and in past history. It was shown for the first time that for one third of 67 patients with APS and thromboses high positive levels of antiphospholipid antibodies (aPL) are associated with low plasminogen levels. The levels of PAI-1 antigen measured by ELIZA method, which detects active, latent and bound with plasminogen activator PAI-1, were opposed with frequency of thromboses in APS patients. Correlation between the high and increased levels of PAI-1 and high positive aPL levels was found for one third of 43 patients with APS and thrombosis. One of the possible mechanisms of this interconnection was considered. It was shown that arterial and, to a more extent, venous thromboses are associated with the 4G/5G polymorphism of PAI-1 gene and high plasma level of the inhibitor in 79% of APS patients. At the presence of the 4G allele patients with SLE+APS had higher PAI-1 levels than patients with PAPS. The obtained results show that measuring the levels of plasminogen and PAI-1 as well as the 4G/5G polymorphism of PAI-1 gene which is associated with thromboses may have the practical significance for identification of high risk of thrombosis in APS patients.
authors.forename: R B
authors.initials: RB
authors.lastname: Aĭsina
authors.forename: L I
authors.initials: LI
authors.lastname: Mukhametova
authors.forename: E V
authors.initials: EV
authors.lastname: Ostriakova
authors.forename: N V
authors.initials: NV
authors.lastname: Seredavkina
authors.forename: L I
authors.initials: LI
authors.lastname: Patrushev
authors.forename: N L
authors.initials: NL
authors.lastname: Patrusheva
authors.forename: T M
authors.initials: TM
authors.lastname: Reshetniak
authors.forename: D A
authors.initials: DA
authors.lastname: Gulin
authors.forename: K B
authors.initials: KB
authors.lastname: Gershkovich
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
authors.forename: S D
authors.initials: SD
authors.lastname: Varfolomeev
mesh_terms: D000328:Adult; D000483:Alleles; D017152:Antibodies, Antiphospholipid / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005838:Genotype; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000235:genetics*
chemical_list: D017152:Antibodies, Antiphospholipid; D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D010958:Plasminogen